US FDA approves NeurogesX's Qutenza patch
This article was originally published in Scrip
Executive Summary
The US FDA has approved NeurogesX's topical anaesthetic Qutenza (capsaicin) 8% patch for the management of neuropathic pain due to postherpetic neuralgia. This is NeurogesX's first product to be approved by the US agency.